Approach to Common Bacterial Infections. Community-Acquired Pneumonia.

Pediatric Clinics of North America

Volumn 60, Issue 2, 2013, Pages 437-453

  Iroh Tam, Pui Ying ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

CAP; Cause; Children; Community acquired pneumonia; Management; Pediatric pneumonia

Indexed keywords

ADAMANTANE DERIVATIVE; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CORTICOSTEROID; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; PNEUMOCOCCUS VACCINE; SIALIDASE INHIBITOR;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTHRALGIA; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; CHILD HOSPITALIZATION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG CHOICE; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A; MEDICAL HISTORY; MIXED INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOPLASMA PNEUMONIA; OSTEOMYELITIS; PARAINFLUENZA VIRUS 1; PHYSICAL EXAMINATION; PLEURA EFFUSION; PLEURA EMPYEMA; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; VIRUS CARRIER; VIRUS PNEUMONIA;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; SEVERITY OF ILLNESS INDEX;

EID: 84875282385     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.12.009     Document Type: Review

References (82)

1. Levine O.S., O'Brien K.L., Deloria-Knoll M., et al. The pneumonia etiology research for child health project: a 21st century childhood pneumonia etiology study. Clin Infect Dis 2012, 54(Suppl 2):S93-S101.
2. Cevey-Macherel M., Galetto-Lacour A., Gervaix A., et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr 2009, 168(12):1429-1436.
3. Juven T., Mertsola J., Waris M., et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000, 19(4):293-298.
4. Michelow I.C., Olsen K., Lozano J., et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004, 113(4):701-707.
5. Baer G., Engelcke G., Abele-Horn M., et al. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents. Eur J Clin Microbiol Infect Dis 2003, 22(12):742-745.
6. Kurz H., Gopfrich H., Wabnegger L., et al. Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. Pediatr Pulmonol 2009, 44(9):873-876.
7. Heiskanen-Kosma T., Paldanius M., Korppi M. Simkania negevensis may be a true cause of community acquired pneumonia in children. Scand J Infect Dis 2008, 40(2):127-130.
8. Greenberg D., Banerji A., Friedman M.G., et al. High rate of Simkania negevensis among Canadian Inuit infants hospitalized with lower respiratory tract infections. Scand J Infect Dis 2003, 35(8):506-508.
9. Cilla G., Onate E., Perez-Yarza E.G., et al. Viruses in community-acquired pneumonia in children aged less than 3 years old: high rate of viral coinfection. J Med Virol 2008, 80(10):1843-1849.
10. Singleton R.J., Bulkow L.R., Miernyk K., et al. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol 2010, 82(7):1282-1290.
11. Jansen R.R., Wieringa J., Koekkoek S.M., et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol 2011, 49(7):2631-2636.
12. Peltola V., Waris M., Osterback R., et al. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008, 197(3):382-389.
13. Iwane M.K., Prill M.M., Lu X., et al. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis 2011, 204(11):1702-1710.
14. Miller E.K., Bugna J., Libster R., et al. Human rhinoviruses in severe respiratory disease in very low birth weight infants. Pediatrics 2012, 129(1):e60-e67.
15. van den Hoogen B.G., de Jong J.C., Groen J., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7(6):719-724.
16. Williams J.V., Edwards K.M., Weinberg G.A., et al. Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis 2010, 201(12):1890-1898.
17. Wolf D.G., Greenberg D., Shemer-Avni Y., et al. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr 2010, 156(1):115-120.
18. Schildgen O., Muller A., Allander T., et al. Human bocavirus: passenger or pathogen in acute respiratory tract infections?. Clin Microbiol Rev 2008, 21(2):291-304. table of contents.
19. Allander T., Andreasson K., Gupta S., et al. Identification of a third human polyomavirus. J Virol 2007, 81(8):4130-4136.
20. Gaynor A.M., Nissen M.D., Whiley D.M., et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007, 3(5):e64.
21. Lin F., Zheng M., Li H., et al. WU polyomavirus in children with acute lower respiratory tract infections, China. J Clin Virol 2008, 42(1):94-102.
22. Yuan X.H., Jin Y., Xie Z.P., et al. Prevalence of human KI and WU polyomaviruses in children with acute respiratory tract infection in China. J Clin Microbiol 2008, 46(10):3522-3525.
23. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348(20):1953-1966.
24. Kuiken T., Fouchier R.A., Schutten M., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003, 362(9380):263-270.
25. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300(5624):1394-1399.
26. Dominguez S.R., Robinson C.C., Holmes K.V. Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado. J Med Virol 2009, 81(9):1597-1604.
27. Harris J.R., Lockhart S.R., Debess E., et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011, 53(12):1188-1195.
28. Sellers B., Hall P., Cine-Gowdie S., et al. Cryptococcus gattii: an emerging fungal pathogen in the southeastern United States. Am J Med Sci 2012, 343(6):510-511.
29. Jadavji T., Law B., Lebel M.H., et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997, 156(5):S703-S711.
30. Langley J.M., Bradley J.S. Defining pneumonia in critically ill infants and children. Pediatr Crit Care Med 2005, 6(Suppl 3):S9-S13.
31. Palafox M., Guiscafre H., Reyes H., et al. Diagnostic value of tachypnoea in pneumonia defined radiologically. Arch Dis Child 2000, 82(1):41-45.
32. Cherian T., John T.J., Simoes E., et al. Evaluation of simple clinical signs for the diagnosis of acute lower respiratory tract infection. Lancet 1988, 2(8603):125-128.
33. Bradley J.S., Byington C.L., Shah S.S., et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011, 53(7):e25-e76.
34. Klig J.E. Office pediatrics: current perspectives on the outpatient evaluation and management of lower respiratory infections in children. Curr Opin Pediatr 2006, 18(1):71-76.
35. Korppi M., Don M., Valent F., et al. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Paediatr 2008, 97(7):943-947.
36. Bettenay F.A., de Campo J.F., McCrossin D.B. Differentiating bacterial from viral pneumonias in children. Pediatr Radiol 1988, 18(6):453-454.
37. Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J 1989, 8(3):143-148.
38. Coote N., McKenzie S. Diagnosis and investigation of bacterial pneumonias. Paediatr Respir Rev 2000, 1(1):8-13.
39. Hazir T., Fox L.M., Nisar Y.B., et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet 2008, 371(9606):49-56.
40. Virkki R., Juven T., Rikalainen H., et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002, 57(5):438-441.
41. Clark J.E., Hammal D., Spencer D., et al. Children with pneumonia: how do they present and how are they managed?. Arch Dis Child 2007, 92(5):394-398.
42. Kin Key N., Araujo-Neto C.A., Nascimento-Carvalho C.M. Severity of childhood community-acquired pneumonia and chest radiographic findings. Pediatr Pulmonol 2009, 44(3):249-252.
43. Harris M., Clark J., Coote N., et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011, 66(Suppl 2):ii1-ii23.
44. Korppi M. Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination?. Pediatr Int 2004, 46(5):545-550.
45. Korppi M., Remes S., Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003, 35(1):56-61.
46. Don M., Valent F., Korppi M., et al. Differentiation of bacterial and viral community-acquired pneumonia in children. Pediatr Int 2009, 51(1):91-96.
47. Lahti E., Peltola V., Waris M., et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax 2009, 64(3):252-257.
48. Scott J.A., Brooks W.A., Peiris J.S., et al. Pneumonia research to reduce childhood mortality in the developing world. J Clin Invest 2008, 118(4):1291-1300.
49. Vuori E., Peltola H., Kallio M.J., et al. Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group. Clin Infect Dis 1998, 27(3):566-572.
50. Dowell S.F., Garman R.L., Liu G., et al. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001, 32(5):824-825.
51. Madhi S.A., Klugman K.P. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004, 10(8):811-813.
52. Gorman S.K., Slavik R.S., Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007, 41(7):1233-1237.
53. Weiss A.K., Hall M., Lee G.E., et al. Adjunct corticosteroids in children hospitalized with community-acquired pneumonia. Pediatrics 2011, 127(2):e255-e263.
54. Bright R.A., Shay D.K., Shu B., et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295(8):891-894.
55. Heinonen S., Silvennoinen H., Lehtinen P., et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010, 51(8):887-894.
56. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002, 360(9336):835-841.
57. Agarwal G., Awasthi S., Kabra S.K., et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 2004, 328(7443):791.
58. Haider B.A., Saeed M.A., Bhutta Z.A. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev 2008, (2). CD005976.
59. Blaschke A.J., Heyrend C., Byington C.L., et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011, 30(4):289-294.
60. Breiman R.F., Butler J.C., Tenover F.C., et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994, 271(23):1831-1835.
61. Richter S.S., Heilmann K.P., Coffman S.L., et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 2002, 34(3):330-339.
62. Richter S.S., Heilmann K.P., Dohrn C.L., et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48(3):e23-e33.
63. Tan T.Q., Mason E.O., Barson W.J., et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 1998, 102(6):1369-1375.
64. Committee on Infectious Diseases The use of systemic fluoroquinolones. Pediatrics 2006, 118(3):1287-1292.
65. Bradley J.S., Arguedas A., Blumer J.L., et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007, 26(10):868-878.
66. Centers for Disease Control and Prevention (CDC) Pertussis-United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002, 51(4):73-76.
67. Duke T., Mgone C.S. Measles: not just another viral exanthem. Lancet 2003, 361(9359):763-773.
68. Allison M.A., Daley M.F., Crane L.A., et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 2006, 149(6):755-762.
69. Ampofo K., Bender J., Sheng X., et al. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics 2008, 122(2):229-237.
70. Finelli L., Fiore A., Dhara R., et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008, 122(4):805-811.
71. Cutts F.T., Zaman S.M., Enwere G., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465):1139-1146.
72. Klugman K.P., Madhi S.A., Huebner R.E., et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14):1341-1348.
73. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
74. Kalaskar A.S., Heresi G.P., Wanger A., et al. Severe necrotizing pneumonia in children, Houston, Texas, USA. Emerg Infect Dis 2009, 15(10):1696-1698.
75. Obando I., Munoz-Almagro C., Arroyo L.A., et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008, 14(9):1390-1397.
76. Black R.E., Cousens S., Johnson H.L., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
77. Woodhead M. Community-acquired pneumonia guidelines: much guidance, but not much evidence. Eur Respir J 2002, 20(1):1-3.
78. Esposito S., Principi N. Unsolved problems in the approach to pediatric community-acquired pneumonia. Curr Opin Infect Dis 2012, 25(3):286-291.
79. WHO guidelines on detecting pneumonia in children. Lancet 1991, 338(8780):1453-1454.
80. World Health Organization Technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities 1991, WHO, Geneva (Switzerland).
81. Kumar P., McKean M.C. Evidence based paediatrics: review of BTS guidelines for the management of community acquired pneumonia in children. J Infect 2004, 48(2):134-138.
82. McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002, 346(6):429-437.